Preview

Medicine and ecology

Advanced search

Study of the structure of the Parkinson’s disease incidence in Karaganda region. Drawing up a routing plan

Abstract

Parkinson’s disease is a progressive, clinically variable neurodegenerative disease, and its prevalence is projected to double over the next 20 years. Practice shows that the diagnosis of Parkinson’s disease is based on clinical manifestations, and the key symptoms are bradykinesia, rigidity and tremor. In addition to motor defects, Parkinson’s disease is also associated with non-motor symptoms, including autonomic dysfunction, depression, anxiety and hallucinations, which can make it difficult to initially diagnose Parkinson’s disease. Therapy for motor defect includes levodopa/carbidopa-based drugs, monoamine oxidase-B inhibitors and dopamine agonists. However, prolonged use and higher doses of levodopa have not demonstrated the ability to slow the progression of the disease, leading over time to dyskinesia and fluctuations in motor symptoms. In this connection, neurosurgical methods of treatment are used in world practice for those who do not achieve adequate control during levodopa therapy. Despite the fact that in Parkinson’s disease, the help of a neurologist is fundamental, a general practitioner is often the first link for patients with early symptoms who need treatment and specialist advice.
The purpose of the study: analysis of clinical cases of Parkinson’s disease in the Karaganda region and drawing up a routing plan.
Materials and methods: a retrospective analysis of outpatient and inpatient records with a verified diagnosis of Parkinson’s disease according to age, gender, clinical stages according to the modified Hyun–Yar scale, the choice of therapy and the identified complications was carried out. An algorithm of actions at the outpatient level is provided, contributing to an effective interdisciplinary approach between a general practitioner, a neurologist and an office of extrapyramidal disorders.
Results. The average age of patients with the incidence of Parkinson’s disease in the Karaganda region was 66.5±9.02. The frequency of occurrence in women (n=138, 62.4%) prevails 1.6 times more than in men (n=83 37.5%). In the structure of morbidity, the most common age group among women was the age from 60 to 69 years (n=66), for men equally from 60 to 79 years (n=54). Alternative methods of neurosurgical treatment have been identified that can be considered in individual patients with PD to improve motor symptoms. The average duration of the disease was 7.3±2.3 (range 49-71 years) when selecting patients for surgical treatment according to international indications for deep brain stimulation.
Conclusion. In this scientific study, a retrospective analysis of gender, age data, clinical stages according to the modified Hen-Yar scale, the choice of therapy and identified complications with an established diagnosis of Parkinson’s disease in the Karaganda region and a comparative characteristic with the available world statistics was carried out, discrepancies in indicators were identified, and the most likely cause of their discrepancy was identified, the main methods of treatment used in international practice were described, followed by comparison in practice in Kazakhstan and the Karaganda region.

About the Authors

M. A. Grigolashvili
NC JSC «Karaganda Medical University»
Kazakhstan

Department of Neurology, Neurosurgery, Psychiatry and Rehabilitation

Karaganda



M. B. Beisembayeva
NC JSC «Karaganda Medical University»
Kazakhstan

Department of Neurology, Neurosurgery, Psychiatry and Rehabilitation

Karaganda



A. A. Rakhimzhanova
NC JSC «Karaganda Medical University»
Kazakhstan

Department of Neurology, Neurosurgery, Psychiatry and Rehabilitation

Karaganda



O. A. Mungalova
NC JSC «Karaganda Medical University»
Kazakhstan

Department of Neurology, Neurosurgery, Psychiatry and Rehabilitation

Karaganda



Zh. S. Zhakhanova
NC JSC «Karaganda Medical University»
Kazakhstan

Department of Neurology, Neurosurgery, Psychiatry and Rehabilitation

Karaganda



References

1. Dorsey ER, Constantinescu R, Thompson JP, Biglan KM, Holloway RG, Kieburtz K, Marshall FJ, Ravina BM, Schifitto G, Siderowf A, Tanner CM. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology. 2007 Jan 30;68(5):384-6. doi: 10.1212/01.wnl.0000247740.47667.03. Epub 2006 Nov 2. PMID: 17082464.

2. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4. doi: 10.1136/jnnp.55.3.181. PMID: 1564476; PMCID: PMC1014720.

3. Kaiyrzhanov R, Zharkinbekova N, Shashkin C, Khaibullin T, Kaishibayeva G, Akhmetzhanov V, Sadykova DZ, Seidinova Z, Taskinbayeva A, Karimova A, Rizig M, Houlden H. Parkinson’s Disease in Kazakhstan: Clinico-Demographic Description of a Large Cohort. J Parkinsons Dis. 2020;10(2):707-709. doi: 10.3233/JPD-191782. PMID: 32144996; PMCID: PMC7242829.

4. Iwaki H, Blauwendraat C, Leonard HL, Makarious MB, Kim JJ, Liu G, Maple-Grødem J, Corvol JC, Pihlstrøm L, van Nimwegen M, Smolensky L, Amondikar N, Hutten SJ, Frasier M, Nguyen KH, Rick J, Eberly S, Faghri F, Auinger P, Scott KM, Wijeyekoon R, Van Deerlin VM, Hernandez DG, Gibbs RJ, Day-Williams AG, Brice A, Alves G, Noyce AJ, Tysnes OB, Evans JR, Breen DP, Estrada K, Wegel CE, Danjou F, Simon DK, Andreassen OA, Ravina B, Toft M, Heutink P, Bloem BR, Weintraub D, Barker RA, Williams-Gray CH, van de Warrenburg BP, Van Hilten JJ, Scherzer CR, Singleton AB, Nalls MA. Differences in the Presentation and Progression of Parkinson’s Disease by Sex. Mov Disord. 2021 Jan;36(1):106-117. doi: 10.1002/mds.28312. Epub 2020 Oct 1. PMID: 33002231; PMCID: PMC7883324.

5. Zhu B, Yin D, Zhao H, Zhang L. The immunology of Parkinson’s disease. SeminImmunopathol. 2022 Sep;44(5):659-672. doi: 10.1007/s00281-022-00947-3. Epub 2022 Jun 8. PMID: 35674826; PMCID: PMC9519672.

6. Udagedara TB, Dhananjalee Alahakoon AM, Goonaratna IK. Vascular Parkinsonism: A Review on Management updates. Ann Indian Acad Neurol. 2019 Jan-Mar;22(1):17-20. doi: 10.4103/aian.AIAN_194_18. PMID: 30692754; PMCID: PMC6327701.

7. Bidesi NSR, Vang Andersen I, Windhorst AD, Shalgunov V, Herth MM. The role of neuroimaging in Parkinson’s disease. J Neurochem. 2021 Nov;159(4):660-689. doi: 10.1111/jnc.15516. Epub 2021 Oct 3. PMID: 34532856; PMCID: PMC9291628.

8. Cohen E, Bay AA, Ni L, Hackney ME. Apathy-Related Symptoms Appear Early in Parkinson’s Disease. Healthcare (Basel). 2022 Jan 4;10(1):91. doi: 10.3390/healthcare10010091. PMID: 35052255; PMCID: PMC8775593.

9. Levin O.S. Bolezn’ Parkinsona / Levin O.S., Fedorova N.V. –. 3-e izd. – M. : MEDpress-inform, 2012. – 352 s. : il. ISBN 978-5-98322-863-4.

10. Chen JJ, Ly AV. Rasagiline: A secondgeneration monoamine oxidase type-B inhibitor for the treatment of Parkinson’s disease. Am J Health Syst Pharm. 2006 May 15;63(10):915-28. doi: 10.2146/ajhp050395. PMID: 16675649.

11. Klinicheskij protokol MZ RK Bolezn’ Parkinsona, odobrenoOb#edinennoj komissiej po kachestvu medicinskih uslugMinisterstva zdravoohranenija i social’nogo razvitija Respubliki Kazahstanot «29» nojabrja 2016 godaProtokol № 16

12. Tokarev A.S., Rozhnova E.N., Sinkin M.V., Tomskij A.A., Rak V.A., Stepanov V.N., Viktorova O.A. Hirurgicheskie metody lechenija bolezni Parkinsona. Rossijskij nevrologicheskij zhurnal. 2021;26(4):4-14. https://doi.org/10.30629/2658-7947-2021-26-4-4-14

13. Sharma VD, Patel M, Miocinovic S. Surgical Treatment of Parkinson’s Disease: Devices and Lesion Approaches. Neurotherapeutics. 2020 Oct;17(4):1525-1538. doi: 10.1007/s13311-020-00939-x. Epub 2020 Oct 28. PMID: 33118132; PMCID: PMC7851282.

14. Malek N. Deep Brain Stimulation in Parkinson’s Disease. Neurol India. 2019 Jul-Aug;67(4):968-978. doi: 10.4103/0028-3886.266268. PMID: 31512617.

15. Kamel WA, Al-Hashel JY. LCIG in treatment of non-motor symptoms in advanced Parkinson’s disease: Review of literature. Brain Behav. 2020 Sep;10(9):e01757. doi: 10.1002/brb3.1757. Epub 2020 Jul 16. PMID: 32677345; PMCID: PMC7507541.

16. Shackleford MR, Mishra V, Mari Z. Levodopa-Carbidopa Intestinal Gel may improve treatment-resistant freezing of gait in Parkinson’s disease. Clin Park Relat Disord. 2022 Jun 8;7:100148. doi: 10.1016/j.prdoa.2022.100148. PMID: 35756075; PMCID: PMC9218161.

17. Gültekin M, Ulukan Ç, Tezcan S, Doğu O, Hanağasi H, Bilgiç B, Bora Tokçaer A, Çakmur R, Elibol B, Mirza M, İnce Günal D, Erer Özbek ÇS, Kenangil G, Yilmaz Küsbeci Ö, Akbostanci MC. Multicenter study of levodopa carbidopa intestinal gel in Parkinson’s disease: the Turkish experience. Turk J Med Sci. 2020 Feb 13;50(1):66-85. doi: 10.3906/sag-1904-150. PMID: 31731332; PMCID: PMC7080356.

18. Gaire S, Kafle S, Bastakoti S, Paudel A, Karki K. Continuous Subcutaneous Apomorphine Infusion in Advanced Parkinson’s Disease: A Systematic Review. Cureus. 2021 Sep 13;13(9):e17949. doi: 10.7759/cureus.17949. PMID: 34660137; PMCID: PMC8514709.

19. Nodel’ M.R. Sovremennye diagnosticheskie kriterii bolezni Parkinsona. Rossijskij zhurnal geriatricheskoj mediciny. 2021;(1):92-96.doi: 10.37586/2686-8636-1-2021-92-96

20. Zagorovskaja, T. B., Shirshov, A. V., & Illarioshkin, S. N. (2010). Algoritm otbora pacientov s bolezn’ju Parkinsona dlja hirurgicheskogo lechenija s primeneniem glubokoj stimuljacii mozga. Nervnye bolezni, (3), 8-12.


Review

For citations:


Grigolashvili M.A., Beisembayeva M.B., Rakhimzhanova A.A., Mungalova O.A., Zhakhanova Zh.S. Study of the structure of the Parkinson’s disease incidence in Karaganda region. Drawing up a routing plan. Medicine and ecology. 2022;(4):10-18. (In Russ.)

Views: 349


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2305-6045 (Print)
ISSN 2305-6053 (Online)